Lumos Diagnostics Holdings Ltd
ASX:LDX
Operating Margin
Lumos Diagnostics Holdings Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
69.6m AUD |
-30%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
6.6T JPY |
29%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
32.8B CHF |
14%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
141.1B DKK |
27%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
10.3B USD |
16%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP |
15%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.4B CHF |
15%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
47.4B CNY |
43%
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.1B USD |
2%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.2B USD |
11%
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
713.7B JPY |
24%
|
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Lumos Diagnostics Holdings Ltd's most recent financial statements, the company has Operating Margin of -30.1%.
You don't have any saved screeners yet